Loading...
Market
Story
Sangamo Regains Hemophilia A Gene Therapy Rights After Pfizer Ends Collaboration, Stock Falls 67%
Dec 30, 2024, 10:54 PM
Sangamo Therapeutics Inc. will regain full development and commercialization rights to its hemophilia A gene therapy program, giroctocogene fitelparvovec, following Pfizer Inc.'s decision to cease development of the treatment. The move comes after positive results from the Phase 3 AFFINE trial, which met its primary and secondary endpoints, demonstrating the potential of the therapy. Sangamo plans to explore all options to advance the program, including seeking a new collaboration partner. The termination of the collaboration with Pfizer, effective April 21, 2025, has led to a significant drop in Sangamo's stock price, falling as much as 67% in extended trading. The decision by Pfizer to abandon the project was unexpected, especially given the recent positive trial data and the potential for regulatory submissions and commercialization.
View original story
Similar markets
Conditional marketing approval • 25%
Phase 3 trial approval • 25%
Phase 2 trial approval • 25%
No major milestone achieved • 25%
BLA submission • 25%
Conditional approval • 25%
Phase III trial initiation • 25%
No progress • 25%
Yes • 50%
No • 50%
Approved in UK, EU, and USA • 25%
Approved in UK only • 25%
Not approved in any major market • 25%
Approved in UK and EU • 25%
Approved in both USA and EU • 25%
Approved in EU only • 25%
Approved in USA only • 25%
Not approved in USA or EU • 25%
Accelerated Approval • 25%
Rejection • 25%
Full Approval • 25%
Conditional Approval • 25%
Successful with no safety issues • 25%
Inconclusive results • 25%
Unsuccessful due to safety issues • 25%
Successful with minor safety issues • 25%